[Mucoviscidosis screening with immunoreactive trypsin. Initial experiences in Austria].
Up to now, 16.338 IRT-measurements have been carried out on dried blood spot specimens; 15.505 of them were taken in the first week of life. Related to a provisionally chosen cut-off point of 750 ng/ml, 134 newborns (= 0.86%) showed an elevated IRT-value and subsequently were recalled between the fourth and sixth week of life for a second IRT-determination. Twenty-five out of 116 reinvestigated children again showed an elevated value, as based on likewise provisional, age-dependent reference values. Four of these children subsequently were identified as CF patients by sweat testing. So far, we did not encounter any false-negative IRT values. We also commenced to establish a profile of reference values for the first twelve weeks of life; as yet, there are not enough data for definitely defining these limits of normality. In conclusion, IRT-screening appears to be a reliable method for identifying CF patients in the newborn period. Our preliminary results indicate an incidence of CF of 1 to 3880 in the southeast of Austria.
Eber
E
E
Universitäts-Kinderklinik, Graz.
Zach
M
M
Engele
H
H
Haas
J
J
Pürstner
P
P
Mutz
I
I
Litscher
H
H
D001317:Austria / Q000453:epidemiology; D003430:Cross-Sectional Studies; D003550:Cystic Fibrosis / Q000097:blood / Q000453:epidemiology / Q000517:prevention & control*; D006801:Humans; D015994:Incidence; D007223:Infant; D007231:Infant, Newborn; D015997:Neonatal Screening / Q000379:methods*; D011863:Radioimmunoassay; D012016:Reference Values; D014357:Trypsin / Q000097:blood*
D014357:Trypsin
Mukoviszidose-Screening mit immunreaktivem Trypsin (IRT). Erste Erfahrungen in Osterreich.